The news is directly about Gilead Sciences and is likely to impact investor sentiment. The lowering of the price target may suggest that the analyst sees less upside potential for the stock, which could influence investors' decisions. However, the maintenance of the Equal-Weight rating indicates that the analyst does not see significant downside risk either, hence the neutral score.